JP2012102112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012102112A5 JP2012102112A5 JP2011279890A JP2011279890A JP2012102112A5 JP 2012102112 A5 JP2012102112 A5 JP 2012102112A5 JP 2011279890 A JP2011279890 A JP 2011279890A JP 2011279890 A JP2011279890 A JP 2011279890A JP 2012102112 A5 JP2012102112 A5 JP 2012102112A5
- Authority
- JP
- Japan
- Prior art keywords
- diarrhea
- constipation
- bowel syndrome
- irritable bowel
- balsalazide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 12
- 206010012735 Diarrhoea Diseases 0.000 claims 11
- 206010010774 Constipation Diseases 0.000 claims 7
- 229960004168 balsalazide Drugs 0.000 claims 7
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 4
- 229960004963 mesalazine Drugs 0.000 claims 4
- -1 4-ASA compound Chemical class 0.000 claims 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- AEUBCEDJMLUFGL-UHFFFAOYSA-N 4-anthracen-2-ylbutanoic acid Chemical group C1=CC=CC2=CC3=CC(CCCC(=O)O)=CC=C3C=C21 AEUBCEDJMLUFGL-UHFFFAOYSA-N 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- 229960004909 aminosalicylic acid Drugs 0.000 claims 2
- 208000024330 bloating Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000002920 convulsive effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004110 olsalazine Drugs 0.000 claims 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 claims 2
- CWLGEPSKQDNHIO-JOBJLJCHSA-N (e)-n-[(e)-benzylideneamino]-1-phenylmethanimine Chemical compound C=1C=CC=CC=1/C=N/N=C/C1=CC=CC=C1 CWLGEPSKQDNHIO-JOBJLJCHSA-N 0.000 claims 1
- 206010000084 Abdominal pain lower Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010013554 Diverticulum Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- CQSRTOJJBONKMC-VHEBQXMUSA-N OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O CQSRTOJJBONKMC-VHEBQXMUSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229950008410 ipsalazide Drugs 0.000 claims 1
- 230000003843 mucus production Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004900563A AU2004900563A0 (en) | 2004-02-06 | Use of Aminosalicylates in Diarrhoea-Predominant Irritable Bowel Syndrome | |
| AU2004900563 | 2004-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551683A Division JP2007520495A (ja) | 2004-02-06 | 2005-02-04 | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012102112A JP2012102112A (ja) | 2012-05-31 |
| JP2012102112A5 true JP2012102112A5 (enExample) | 2013-02-28 |
| JP5558456B2 JP5558456B2 (ja) | 2014-07-23 |
Family
ID=34831684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551683A Withdrawn JP2007520495A (ja) | 2004-02-06 | 2005-02-04 | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
| JP2011279890A Expired - Lifetime JP5558456B2 (ja) | 2004-02-06 | 2011-12-21 | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551683A Withdrawn JP2007520495A (ja) | 2004-02-06 | 2005-02-04 | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20070213304A1 (enExample) |
| EP (2) | EP2361620B1 (enExample) |
| JP (2) | JP2007520495A (enExample) |
| AT (1) | ATE554752T1 (enExample) |
| AU (1) | AU2005209948B2 (enExample) |
| CA (1) | CA2555304C (enExample) |
| ES (1) | ES2571252T3 (enExample) |
| HU (1) | HUE029189T2 (enExample) |
| NZ (1) | NZ549661A (enExample) |
| PL (1) | PL2361620T3 (enExample) |
| WO (1) | WO2005074908A1 (enExample) |
| ZA (1) | ZA200607435B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029189T2 (en) | 2004-02-06 | 2017-02-28 | Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust | The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome |
| EP2586427A3 (en) * | 2005-08-24 | 2013-05-29 | Salix Pharmaceuticals, Inc. | Balsalazide formulations and manufacture thereof |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| RU2297835C1 (ru) * | 2005-09-26 | 2007-04-27 | Закрытое акционерное общество "Партнер" | Препарат для лечения неинфекционных воспалительных болезней кишечника |
| JP2011500552A (ja) * | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | 胃腸障害を処置するための医薬用組み合わせおよび組成物 |
| NZ598716A (en) | 2009-10-26 | 2014-08-29 | Borody Thomas J | Novel enteric combination therapy |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791889A (fr) | 1971-11-26 | 1973-05-24 | Pharmacia Ab | Nouveaux derives de la pyridine |
| US4298595A (en) | 1978-12-20 | 1981-11-03 | Dynapol | Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
| US4960765A (en) | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| JPS57500432A (enExample) | 1980-03-20 | 1982-03-11 | ||
| EP0039306B1 (de) | 1980-03-28 | 1984-01-11 | Ciba-Geigy Ag | Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung |
| US4412922A (en) | 1980-07-02 | 1983-11-01 | Abcor, Inc. | Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions |
| US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4562024A (en) | 1982-07-06 | 1985-12-31 | Sterling Drug Inc. | Process for preparing granulate containing poorly compressible medicinally active matter |
| US4558552A (en) * | 1983-07-08 | 1985-12-17 | Reitter Stucco, Inc. | Building panel and process for making |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| SE8405924L (sv) | 1984-11-23 | 1986-05-24 | Pharmacia Ab | Nya azoforeningar |
| US4781925A (en) | 1986-03-06 | 1988-11-01 | American Home Products Corporation | Calcium supplement compressed tablets |
| US5374430A (en) | 1986-09-18 | 1994-12-20 | London School Of Pharmacy | Pharmaceutical formulation |
| DE3887353T2 (de) | 1987-10-12 | 1994-05-05 | Capability Services Pty Ltd | Behandlungsverfahren für magen-darm-krankheiten. |
| US5064637A (en) | 1989-05-30 | 1991-11-12 | Board Of Regents, The University Of Texas System | Substituted sulfonamide derivatives which inhibit allergic reactions |
| US5095073A (en) | 1990-03-02 | 1992-03-10 | Exxon Research And Engineering Company | Water soluble rigid rod sulfonated aromatic polyamide |
| SE9003296L (sv) | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | Foerfarande foer att formulera laekemedel |
| AU652191B2 (en) * | 1990-10-22 | 1994-08-18 | Centre For Digestive Diseases Pty Ltd | Treatment of non-inflammatory and non-infectious bowel disorders |
| US5519014A (en) * | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
| JP3425441B2 (ja) * | 1990-10-22 | 2003-07-14 | ガストロ サービシイズ ピーティーワイ リミテッド | 非炎症性及び非感染性腸障害の処置 |
| WO1992016214A1 (en) * | 1991-03-15 | 1992-10-01 | Norwich Eaton Pharmaceuticals Inc. | The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d) |
| DE59307753D1 (de) | 1992-03-11 | 1998-01-15 | Asta Medica Ag | Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen |
| US5498608A (en) * | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| JPH08169847A (ja) | 1994-12-16 | 1996-07-02 | Morishita Roussel Kk | 固形製剤 |
| US5905073A (en) | 1995-01-06 | 1999-05-18 | Salix Pharmaceuticals, Inc. | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| SE9700934D0 (sv) | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
| WO1998043667A1 (en) | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| US20030078205A1 (en) | 2001-07-31 | 2003-04-24 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| AUPO665397A0 (en) * | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
| US6144381A (en) | 1997-05-14 | 2000-11-07 | International Business Machines Corporation | Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds |
| DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| US6489447B1 (en) | 1998-05-06 | 2002-12-03 | Genentech, Inc. | Protein purification |
| US5927500A (en) | 1998-06-09 | 1999-07-27 | Milliken & Company | Pharmaceutical containment package |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| EP1098634A4 (en) | 1998-07-20 | 2006-10-25 | Smithkline Beecham Corp | EPROSARTAN CONTAINING MORE EFFECTIVE FORMULATIONS IN ORAL SOLID PHARMACEUTICAL FORM |
| KR20000011247A (ko) | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
| US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| US20030138399A1 (en) | 1999-05-14 | 2003-07-24 | Anton Peter A. | Anti-inflammatory therapy for inflammatory mediated infection |
| CA2420576C (en) | 2000-08-29 | 2005-06-14 | Nobex Corporation | Immunoregulatory compounds, derivatives thereof and their use |
| CA2421114C (en) * | 2000-08-29 | 2010-12-07 | Nobex Corporation | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| US6562871B1 (en) | 2000-11-06 | 2003-05-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Dry granulation of pharmaceutical formulation comprising mexiletine |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
| AU2003226752A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine base |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| JPWO2004082715A1 (ja) | 2003-03-20 | 2006-06-22 | エーザイ株式会社 | 炎症性腸疾患治療剤としての併用医薬 |
| US7825106B2 (en) | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| WO2005030173A1 (en) * | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Colon-specific drug delivery using interpolymer complexations |
| HUE029189T2 (en) | 2004-02-06 | 2017-02-28 | Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust | The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome |
| EP2586427A3 (en) | 2005-08-24 | 2013-05-29 | Salix Pharmaceuticals, Inc. | Balsalazide formulations and manufacture thereof |
| US8921344B2 (en) | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| WO2008033125A1 (en) | 2006-09-13 | 2008-03-20 | The Procter & Gamble Company | Methods of treatment for ulcerative colitis using aminosalicylate |
-
2005
- 2005-02-04 HU HUE11000447A patent/HUE029189T2/en unknown
- 2005-02-04 WO PCT/AU2005/000142 patent/WO2005074908A1/en not_active Ceased
- 2005-02-04 AT AT05700172T patent/ATE554752T1/de active
- 2005-02-04 ZA ZA200607435A patent/ZA200607435B/xx unknown
- 2005-02-04 ES ES11000447T patent/ES2571252T3/es not_active Expired - Lifetime
- 2005-02-04 EP EP11000447.0A patent/EP2361620B1/en not_active Expired - Lifetime
- 2005-02-04 EP EP05700172A patent/EP1720536B1/en not_active Expired - Lifetime
- 2005-02-04 US US10/588,558 patent/US20070213304A1/en not_active Abandoned
- 2005-02-04 AU AU2005209948A patent/AU2005209948B2/en not_active Expired
- 2005-02-04 NZ NZ549661A patent/NZ549661A/en not_active IP Right Cessation
- 2005-02-04 CA CA2555304A patent/CA2555304C/en not_active Expired - Lifetime
- 2005-02-04 PL PL11000447.0T patent/PL2361620T3/pl unknown
- 2005-02-04 JP JP2006551683A patent/JP2007520495A/ja not_active Withdrawn
-
2011
- 2011-12-21 JP JP2011279890A patent/JP5558456B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-16 US US13/742,837 patent/US20130231308A1/en not_active Abandoned
-
2014
- 2014-12-30 US US14/585,911 patent/US9937190B2/en not_active Expired - Lifetime
-
2018
- 2018-02-28 US US15/907,566 patent/US10328088B2/en not_active Expired - Lifetime
-
2019
- 2019-05-09 US US16/407,458 patent/US20200101090A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012102112A5 (enExample) | ||
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| JP2014534239A5 (enExample) | ||
| IL203448A (en) | History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them | |
| JP2015518818A5 (enExample) | ||
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| WO2011160062A3 (en) | Compositions and methods for treating inflammatory conditions | |
| BR112013020536A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2 | |
| AR070813A1 (es) | Nuevos derivados de 1- bencil -3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1 | |
| WO2009045543A8 (en) | Treatment of conditions related to shock | |
| JP2010209101A5 (enExample) | ||
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| RU2017130289A (ru) | Ценикривирок для лечения фиброза | |
| MX357507B (es) | Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato. | |
| BRPI0924418A2 (pt) | composições e métodos para a prevenção e o tratamento de obesidade e síndrome metabólica relacionada à obesidade | |
| JP2012525422A5 (enExample) | ||
| JP2016508368A5 (enExample) | ||
| RU2011131609A (ru) | Способ получения литиевой соли коменовой кислоты и применение ее как антиоксидантного, стресс- и нейропротекторного средства | |
| Dreshaj et al. | Clinical role of cefixime in community-acquired infections | |
| TWI455714B (zh) | 治療泛素化包涵體額顳葉退化症之方法 | |
| JP2018513862A5 (enExample) | ||
| LT2576495T (lt) | Nauji mesalazino dariniai, jų gavimo būdas ir naudojimas uždegiminių žarnyno ligų gydymui | |
| Ohia et al. | Current trend in the pharmacotherapy of digestive disorders | |
| WO2015077693A3 (en) | Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microran 146-a antagonists | |
| RU2020127436A (ru) | Композиция для лечения пациента, страдающего язвенным колитом, и применение композиции в качестве лекарственного средства |